Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives
No assurance can be given as to whether any particular financial or strategic alternative will be recommended or undertaken and, if so, upon what terms and conditions.
For more information, visit the Company’s website at www.SiennaBio.com.
This press release contains forward-looking statements, including but not limited to statements regarding the potential of a capital raising transaction and the exploration of other financial and strategic alternatives. Such forward-looking statements involve substantial risks and uncertainties that could cause Sienna’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, Sienna’s need to raise substantial additional capital, uncertainties inherent in the pharmaceutical drug and medical device development processes, including regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing pharmaceutical drug and medical device products, Sienna’s ability to successfully protect and defend its intellectual property, and Sienna’s ability to consummate a capital raising or other financial or strategic transaction. Sienna undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Sienna’s most recent Annual Report on Form 10-K and any subsequent current and periodic reports filed with the
Source: Sienna Biopharmaceuticals, Inc.